Keramatian Kamyar, Chithra Nellai K, Yatham Lakshmi N
Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
Focus (Am Psychiatr Publ). 2023 Oct;21(4):344-353. doi: 10.1176/appi.focus.20230009. Epub 2023 Oct 15.
Bipolar disorder is a complex and heterogeneous psychiatric condition that affects more than 2% of the population. The assessment and treatment of bipolar disorder can be a challenge for clinicians, given its clinical complexity and the rapidly changing treatment landscape with the growing range of treatment options that are becoming available for various phases of the illness. To help clinicians navigate the complexity involved in the assessment and management of bipolar disorder, the guidelines of the 2018 Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) synthesized the evidence on the efficacy, safety, and tolerability of treatments for bipolar disorder and translated it into first-, second-, and third-line treatment recommendations. The main objective of this contribution is to provide clinicians with a summary of the 2018 CANMAT/ISBD guideline recommendations with the addition of any new evidence for the treatment of bipolar disorder across the lifespan.
双相情感障碍是一种复杂的异质性精神疾病，影响着超过2%的人口。鉴于双相情感障碍的临床复杂性以及随着针对该疾病不同阶段的治疗选择范围不断扩大，治疗格局迅速变化，对临床医生而言，双相情感障碍的评估和治疗可能是一项挑战。为帮助临床医生应对双相情感障碍评估和管理中的复杂性，2018年加拿大情绪与焦虑治疗网络（CANMAT）和国际双相情感障碍协会（ISBD）的指南综合了双相情感障碍治疗的疗效、安全性和耐受性方面的证据，并将其转化为一线、二线和三线治疗建议。本文的主要目的是为临床医生提供2018年CANMAT/ISBD指南建议的总结，并补充双相情感障碍全生命周期治疗的任何新证据。
